A Dose Ranging Study to Examine TDS-Testosterone 5% (PARC-T-D)

A Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine TDS-Testosterone 5% in Adult Male Subjects

This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.

Study Overview

• Status: Not yet recruiting
• Conditions: Hypogonadotropism
• Intervention / Treatment: Drug: Testosterone; Device: Pump Sprayer

Detailed Description

48 Patients will be enrolled following 2 independent verifying blood tests of their diagnosis of Hypogonadism. there will be 4 cohorts of 12 subjects, each receiving doses of the trail materials, titrated by means of number of sprays applied. Doses will range from 10 to 70 mgs Testosterone.

• Study Type: Interventional
• Enrollment (Estimated): 48
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Shern L. Chew, M.D., Ph.D.; Phone Number: 011-44-20 034 6227; Email: sl.chew@thelondonclinic.co.uk
• Study Contact Backup: Name: Chandan AS Alam, MD; Phone Number: 011-44-7785-717596; Email: calam@tdsc.us

Study Locations

• United Kingdom
  • London, United Kingdom, NW1 4LJ
    • Advanced Therapies Centre, The London Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Hypogonadal Male subjects - morning testosterone level ≤300 ng/dL (10.4 ng/L).
2. 18 and 75 years of age, inclusive.
3. The subject is willing and able to read, understand the Subject Information Sheet and provide written informed consent.
4. The subject has a body mass index (BMI) within 18-30 kg/m2.
5. The subject is in otherwise good health as determined by medical history and physical examination.
6. The subject is a non-smoker.
7. The subject must agree to comply with the placement of an indwelling catheter on two separate occasions and the drawing of blood samples for the pharmacokinetic assessments.
8. The subject is willing and able to comply with all testing and requirements defined in the protocol.
9. The subject is willing and able to return to the study site for all visits.

Exclusion Criteria:

1. The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator, particularly an elevated PSA reading >4.0 ng/ml or ALT and AST greater than 2 times the upper limit of normal, clinically significant anemia (hematocrit <35%) or renal dysfunction (creatinine >2mg/dL), active deep vein thrombosis, thromboembolic disorders or history of these conditions.
2. The subject has had a clinically significant illness within 30 days preceding entry into this study.
3. The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
4. The subject has a known allergy or history of hypersensitivity to Testosterone or similar compounds.
5. The subject has used any prescription medication within 14 days or over-the-counter (OTC) medication or alcohol within 48 hours of dosing or intends to use any prescription or OTC medication during the study that may interfere with the evaluation of study medication.
6. The subject has donated or lost a significant volume of blood (>450 mL) within four (4) weeks of the study, and their haemoglobin concentration and haematocrit have not returned to within 5% of normal.
7. The subject has a Hematocrit level > 51%
8. The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.
9. Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
10. Subjects who have received an investigational drug or have used an investigational device in the 30 days prior to study entry.
11. Subjects with an American Urological Association System Index for Prostatism score greater than 7
12. Subjects with a history of prostate or breast carcinoma.
13. Subjects with prostatic mass on screening physical examination.
14. Subjects with a history of significant skin disease.
15. Subjects with a history of sleep apnea.
16. Subject with a partner with a history of breast cancer.
17. Subject with a partner of child bearing potential who is not willing to use adequate contraception for the duration of the trial.
18. Subject whose partner is pregnant.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Forearm dose; Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.	Drug: Testosterone; 10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.; Device: Pump Sprayer; A dose of product solution is delivered by means of a metered pump spray.
Active Comparator: Chest Dose; Half of Ss will receive their dose of Testosterone on the chest.	Drug: Testosterone; 10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.; Device: Pump Sprayer; A dose of product solution is delivered by means of a metered pump spray.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose Range Measure of serum levels of testosterone in response to varying doses	A pharmacokinetic measure of serum levels of testosterone in response to varying doses of from 10 to 70 mgs of Testosterone.	1 week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dermal Safety as measured by	Incidence of treatment-emergent side effects.	1 Week

Collaborators and Investigators

• Sponsor: Transdermal Delivery Solutions Corp
• Collaborators: Advanced Therapies Centre, The London Clinic
• Investigators: Principal Investigator: Shern L. Chew, M.D., Ph.D., Consultant Physician and Professor of Endocrine Medicine

Publications and helpful links

General Publications

• Chik Z, Johnston A, Tucker AT, Chew SL, Michaels L, Alam CA. Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. Br J Clin Pharmacol. 2006 Mar;61(3):275-9. doi: 10.1111/j.1365-2125.2005.02542.x.

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): February 1, 2027

Study Registration Dates

• First Submitted: July 3, 2013
• First Submitted That Met QC Criteria: July 9, 2013
• First Posted (Estimated): July 10, 2013

Study Record Updates

• Last Update Posted (Estimated): September 3, 2025
• Last Update Submitted That Met QC Criteria: September 2, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: Phase II; Male Hormone Replacement; Multiple Dose; Single Period; Dose Ranging; Adult Male Subjects; Testosterone Replacement
• Additional Relevant MeSH Terms: Endocrine System Diseases; Gonadal Disorders; Hypogonadism; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Polycyclic Compounds; Steroids; Fused-Ring Compounds; Gonadal Steroid Hormones; Gonadal Hormones; Androstenes; Androstanes; Androstenols; Testosterone Congeners; Testosterone
• Other Study ID Numbers: PARC-Testosterone-D1/09/13; 2013-001766-42 (EudraCT Number); IRAS project ID: 146877 (Other Identifier: London - West London & GTAC Research Ethics Committee)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes